Lung Cancer

Lung-cancer work gives shikonin a plausible foothold, especially in EGFR-driven disease.

The main evidence is still preclinical and some of the most interesting findings come from derivatives rather than native shikonin.

Why lung cancer is a logical target

Many non-small-cell lung cancers depend on EGFR and PI3K/AKT/mTOR signalling.

These pathways drive survival, proliferation, and acquired treatment resistance.

Shikonin and some of its derivatives appear to interfere with that axis.

Key evidence

Reported findings include:

• inhibition of PI3K/AKT/mTOR signalling in lung-cancer cell lines

• reduced proliferation and survival signalling

• derivative-linked sensitisation of gefitinib-resistant NSCLC through TrxR inhibition and EGFR proteasomal degradation

The derivative work matters, but it should not be overstated as proof for native shikonin.

Why this matters

Gefitinib resistance remains a major problem in EGFR-mutant disease.

A compound class that can re-open EGFR vulnerability remains interesting even when the evidence is still early.

Limits

• much of the strongest sensitisation work uses derivatives, not native shikonin

• most models are EGFR-focused, not KRAS- or ALK-driven disease

• no robust immune-competent in vivo literature

• no human data exists

Bottom line

Lung cancer is a real but secondary shikonin setting.

The pathway logic is sound.

The strongest specific sensitisation signal currently belongs more to derivative compounds than to the native molecule.

References

Shikonin anticancer activity against lung cancer through PI3K/AKT/mTOR. ScienceDirect (2025).
https://www.sciencedirect.com/science/article/abs/pii/S2950199726001114

ER-mediated anti-tumor effects — EGFR proteasomal degradation and gefitinib sensitisation context. European Journal of Pharmacology.
https://www.sciencedirect.com/science/article/abs/pii/S0014299919306193